This follow-up report is submitted to fda in accord with applicable regulations ¿ and as indicated by terumo cardiovascular systems in the initial report submitted to the fda on september 19, 2018.(b)(4).The returned sample was visually inspected.It was discovered that the purge line and sampling lone had been cut off, no other anomaly found.The sample, after having been rinsed and dried was tested for its gas transfer performance in accordance with the factory's shipping inspection protocol in which no anomalies were found and the obtained values meet the factory specification.From the available information, with the absence of the involved pump record, the cause of this complaint cannot be determined.All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|